New Treatments for Geographic Atrophy
FDA-Approved Complement Inhibitors
According to the AAO (2023), the FDA approved pegcetacoplan on February 17, 2023, as the first-ever drug approved for geographic atrophy. Pegcetacoplan is a complement C3 inhibitor delivered by intravitreal injection on a monthly or every-other-month schedule. Phase 3 data at 24 months showed a 22 percent and 19 percent reduction in GA lesion growth rate with monthly injections across two pivotal trials, according to published data (American Journal of Ophthalmology, 2024). The drug does not restore lost vision; it slows the rate at which atrophic patches expand.
According to the AAO (2023-2024), monthly dosing carries a higher risk of wet AMD conversion than every-other-month dosing: 12 percent monthly versus 7 percent every-other-month versus 3 percent in controls at 24 months. Rare occlusive retinal vasculitis has also been reported post-approval.
According to the AAO (2023), the FDA approved avacincaptad pegol in August 2023 for geographic atrophy. This drug inhibits complement factor C5, a target downstream of C3 in the complement cascade. The GATHER1 trial showed a 27 percent reduction in GA lesion growth rate, and the GATHER2 trial showed a 14 percent reduction over 12 months with monthly 2 mg intravitreal dosing, according to published data (PMC, 2024). Like pegcetacoplan, avacincaptad pegol carries an increased risk of wet AMD conversion compared to no treatment.
According to the AAO (2024), avacincaptad pegol may have fewer adverse events than pegcetacoplan based on comparative data, though both drugs target the same underlying complement-driven disease process.
Before 2023, geographic atrophy had no FDA-approved treatment. Patients could only monitor their condition and manage risk factors. These complement inhibitors give retina specialists the first tools to slow GA progression. According to the AAO (2024), the AMD Preferred Practice Pattern now includes guidance on complement inhibitor use in geographic atrophy, reflecting the rapid evolution of GA treatment standards.
Non-Injectable Treatment Options
According to the AAO and Ophthalmology Times (2024-2025), the FDA authorized a photobiomodulation light delivery system in November 2024 as the first non-invasive FDA-authorized treatment for dry AMD. The LIGHTSITE III trial enrolled 100 patients over 13 months and showed a mean improvement of more than 5 ETDRS letters and a 73 percent reduction in incident GA onset compared to sham treatment at 24 months.
This treatment uses specific wavelengths of light delivered to the retina through a tabletop device. The protocol involves 9 short sessions over 3 to 5 weeks, repeated every 4 months for a 2-year course. Unlike injectable treatments, photobiomodulation requires no needles and has a different side effect profile.
Photobiomodulation and complement inhibitors work through different mechanisms. Complement inhibitors suppress the immune cascade that destroys retinal cells. Photobiomodulation uses light energy to stimulate cellular repair processes in the retina. Your retina specialist may recommend one approach or explore whether combining them offers additional benefit as more research becomes available.
Your retina specialist evaluates your GA lesion size, location, and progression rate to determine which treatment approach fits your situation. Patients with earlier-stage GA and more remaining central vision have the most to gain from slowing progression. Both injectable and non-injectable options require ongoing treatment commitment to maintain their benefit over time.
Treatments in Development
According to the AAO (2024), a global phase 3 trial is underway for a novel neuroprotective complement C1q inhibitor, with results expected in the second half of 2026. This drug targets the earliest trigger of the complement cascade, potentially offering a different point of intervention than C3 or C5 inhibitors. Your retina specialist can discuss clinical trial opportunities if you are interested in investigational treatments.
According to the NEI (2023-2024), the NEI launched a first-in-human U.S. clinical trial of patient-derived stem cell therapy to replace dying retinal pigment epithelium cells in geographic atrophy. This approach aims to restore the RPE layer rather than just slowing its destruction, which would represent a different treatment paradigm. Results from early-phase trials will determine whether this approach is safe and feasible for broader use.
The pace of GA treatment development has accelerated since 2023. Multiple drug mechanisms, delivery methods, and combination approaches are under investigation. Patients diagnosed with GA today have more treatment options than at any previous time, and the pipeline of emerging therapies continues to grow. Your retina specialist stays current with developments and can recommend the best available option for your disease stage.
Living With GA Treatment
According to the AAO (2023), neither pegcetacoplan nor avacincaptad pegol restores vision. Both drugs slow the rate of atrophic lesion growth, preserving remaining vision over time. Patients must understand that treatment prevents future loss rather than reversing existing damage. Starting treatment while you still have usable central vision gives you the most benefit.
Injectable GA treatments require ongoing monthly or every-other-month office visits for intravitreal injections. Photobiomodulation requires periodic multi-session treatment cycles. Both approaches demand a long-term commitment to maintain their benefit. Your retina specialist will discuss the practical aspects of each option, including visit frequency, duration, and monitoring requirements.
According to the AAO (2023-2024), patients receiving complement inhibitors face an elevated risk of converting to wet AMD and must be monitored at every treatment visit. This risk is higher with monthly versus every-other-month pegcetacoplan dosing. Your retina specialist checks OCT imaging at each visit to detect early signs of neovascularization. If wet AMD develops, anti-VEGF injections can treat it, often alongside your ongoing GA therapy.
Questions About New GA Treatments
Your retina specialist will recommend an approach based on your lesion characteristics, risk factors, and treatment preferences. Pegcetacoplan offers monthly or every-other-month dosing. Avacincaptad pegol is monthly only. Photobiomodulation is non-invasive. Your doctor weighs the evidence, your medical history, and practical considerations to guide the decision.
Research on combining complement inhibitors with photobiomodulation or other approaches is still in early stages. Your retina specialist can discuss whether any combination approaches are being studied at your treatment center. For now, most patients receive one GA-specific treatment at a time.
Your retina specialist measures GA lesion growth over time using OCT imaging. Meaningful comparisons typically require at least six to twelve months of treatment. You will not feel the medication working or see vision improvement; the benefit is measured by slowed lesion expansion on imaging compared to expected untreated progression.
You can start treatment at any time. Whether you were diagnosed recently or years ago, your retina specialist can evaluate your current lesion size and location and determine whether treatment could benefit you. Earlier treatment preserves more remaining vision, but starting late is still better than not starting.
Medicare Part B covers physician-administered intravitreal injections for GA when medically necessary. Some commercial and Medicare Advantage plans may require prior authorization. Photobiomodulation coverage is still evolving. Your retina specialist can verify your coverage before starting treatment and connect you with manufacturer assistance programs if needed.
Explore Your Treatment Options
Geographic atrophy treatment has entered a new era. Talk to your retina specialist about which approved or emerging therapy could help slow your disease progression and preserve the central vision you depend on.